[go: up one dir, main page]

BRPI0810821A8 - Derivados de anéis aromáticos de seis membros contendo nitrogênio e produtos farmacêuticos contendo os mesmos - Google Patents

Derivados de anéis aromáticos de seis membros contendo nitrogênio e produtos farmacêuticos contendo os mesmos

Info

Publication number
BRPI0810821A8
BRPI0810821A8 BRPI0810821A BRPI0810821A BRPI0810821A8 BR PI0810821 A8 BRPI0810821 A8 BR PI0810821A8 BR PI0810821 A BRPI0810821 A BR PI0810821A BR PI0810821 A BRPI0810821 A BR PI0810821A BR PI0810821 A8 BRPI0810821 A8 BR PI0810821A8
Authority
BR
Brazil
Prior art keywords
group
derivatives
pharmaceutical products
aromatic rings
same
Prior art date
Application number
BRPI0810821A
Other languages
English (en)
Inventor
Takemoto Naohiro
Murata Kenji
Murayama Norihito
Yamada Chikaomi
Original Assignee
Asubio Pharma Co Ltd
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asubio Pharma Co Ltd, Daiichi Sankyo Co Ltd filed Critical Asubio Pharma Co Ltd
Publication of BRPI0810821A2 publication Critical patent/BRPI0810821A2/pt
Publication of BRPI0810821A8 publication Critical patent/BRPI0810821A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS DE ANÉIS AROMÁTICOS DE SEIS MEMBROS CONTENDO NITROGÊNIO E PRODUTOS FARMACÊUTICOS CONTENDO OS MESMOS. A presente invenção refere-se a um composto que tem a capacidade de promover crescimento axonal em combinação com a capacidade de promover angiogênese e,portanto pode ser usado para reduzir lesões nervosas centrais tais como lesão de cabeça e lesão da medula espinhal, enfarte cerebral, doenças cardíacas isquêmicas tais como enfarte do miocárdio e angina orgânica, doença oclusivas arteriais periféricas tais como isquemia de membro critico, ou efeitos secundários destas doenças. Especificamente o composto é representado pela seguinte fórmula (I): na qual grupo Nx é preferencialmente um anel aromático de 6 membros contendo dois átomos de nitrogênio: R0,R1 e R2 são cada independentemente um átomo de hidrogênio, um grupo alquila, um grupo amino ou similares: E é um átomo de oxigênio ou um grupo -NR8(em que R8 é um grupo alquila ou similares );n é um número inteiro de 0 a 5; x e y são cada uma ligação conectante, um grupo cicloalquila, - CO - ou similares; e Q é um átomo de hidrogênio ou um grupo fenil.
BRPI0810821A 2007-04-27 2008-04-25 Derivados de anéis aromáticos de seis membros contendo nitrogênio e produtos farmacêuticos contendo os mesmos BRPI0810821A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007118768 2007-04-27
PCT/JP2008/058081 WO2008139894A1 (ja) 2007-04-27 2008-04-25 含窒素芳香族６員環誘導体並びにそれらを含む医薬

Publications (2)

Publication Number Publication Date
BRPI0810821A2 BRPI0810821A2 (pt) 2014-10-29
BRPI0810821A8 true BRPI0810821A8 (pt) 2015-09-15

Family

ID=40002110

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810821A BRPI0810821A8 (pt) 2007-04-27 2008-04-25 Derivados de anéis aromáticos de seis membros contendo nitrogênio e produtos farmacêuticos contendo os mesmos

Country Status (18)

Country Link
US (4) US8592435B2 (pt)
EP (2) EP2679586B1 (pt)
JP (1) JP5197584B2 (pt)
KR (1) KR101456316B1 (pt)
CN (2) CN101730691A (pt)
AU (1) AU2008249329C1 (pt)
BR (1) BRPI0810821A8 (pt)
CA (1) CA2683941C (pt)
CY (1) CY1115377T1 (pt)
DK (1) DK2151439T3 (pt)
ES (2) ES2453590T3 (pt)
HR (1) HRP20140326T1 (pt)
MX (1) MX2009011369A (pt)
PL (1) PL2151439T3 (pt)
PT (1) PT2151439E (pt)
RU (1) RU2470927C2 (pt)
SI (1) SI2151439T1 (pt)
WO (1) WO2008139894A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112284C2 (uk) * 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні 5-фторпіримідинону
NZ597638A (en) * 2009-08-07 2014-06-27 Dow Agrosciences Llc 5-fluoro-2-oxopyrimidine- 1(2h)-carboxylate derivatives
EP2938194B1 (en) 2012-12-28 2019-11-27 Adama Makhteshim Ltd. N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2h)-carboxylate derivatives
US9321734B2 (en) 2012-12-28 2016-04-26 Dow Agrosciences Llc N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1(2H)-carboxamide derivatives
RU2644014C2 (ru) 2012-12-31 2018-02-07 Адама Мактешим Лтд. Производные 3-алкил-5-фтор-4-замещенного-имино-3,4-дигидропиримидин-2(н)-она в качестве фунгицидов
WO2016047662A1 (ja) * 2014-09-25 2016-03-31 第一三共株式会社 脳卒中の治療剤
WO2016086105A1 (en) * 2014-11-25 2016-06-02 Shriners Hospitals For Children MODEL SYSTEMS FOR SCREENING MODULATORS OF mTOR SIGNALING
CN114570418B (zh) * 2022-02-22 2023-10-17 陕西延长石油（集团）有限责任公司 一种羟基乙酸甲酯制备肌氨酸甲酯及肌氨酸的催化剂及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1260474A (en) 1984-12-03 1989-09-26 Raymond A. Stokbroekx Benzoxazol- and benzothiazolamine derivatives
GB8912700D0 (en) 1989-06-02 1989-07-19 Shell Int Research Herbicidal compounds
DE68914197T2 (de) * 1988-06-20 1994-11-10 Ihara Chemical Ind Co Alkansäurederivate und herbizide Mittel.
JP2771604B2 (ja) * 1988-06-20 1998-07-02 クミアイ化学工業株式会社 除草剤及びその有効成分となる新規なアルカン酸誘導体
GB8917476D0 (en) 1989-07-31 1989-09-13 Shell Int Research Sulphonamide herbicides
AU762345B2 (en) 1998-10-16 2003-06-26 Asubio Pharma Co., Ltd. Aminophenoxyacetic acid derivatives as neuroprotectants
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AU784930B2 (en) * 2000-04-13 2006-08-03 Asubio Pharma Co., Ltd. Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
CN100384838C (zh) * 2001-04-27 2008-04-30 三菱制药株式会社 新的苄基哌啶化合物
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
BR0312217A (pt) 2002-06-24 2005-05-10 Acadia Pharm Inc Compostos, métodos de inibição da atividade/ativação de um receptor monoaminérgico e método de tratamento de condição doentia associada a um receptor de monoaminergético
MY142362A (en) * 2004-01-29 2010-11-30 Otsuka Pharma Co Ltd Pharmaceutical composition for promoting angiogenesis
JP4916115B2 (ja) 2004-01-29 2012-04-11 大塚製薬株式会社 血管新生促進剤
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
JP2009529039A (ja) 2006-03-07 2009-08-13 アストラゼネカ・アクチエボラーグ ピペリジン誘導体、それらの製造法、治療剤としてのそれらの使用およびそれらを含む医薬組成物

Also Published As

Publication number Publication date
CA2683941C (en) 2014-08-12
HRP20140326T1 (hr) 2014-05-09
JPWO2008139894A1 (ja) 2010-07-29
RU2470927C2 (ru) 2012-12-27
BRPI0810821A2 (pt) 2014-10-29
CN103396399B (zh) 2015-04-29
CA2683941A1 (en) 2008-11-20
PT2151439E (pt) 2014-04-10
EP2151439B1 (en) 2014-02-26
US8685989B2 (en) 2014-04-01
CY1115377T1 (el) 2017-01-04
CN101730691A (zh) 2010-06-09
EP2151439A4 (en) 2012-08-01
US9139559B2 (en) 2015-09-22
US20140336209A1 (en) 2014-11-13
AU2008249329C1 (en) 2013-07-04
AU2008249329B2 (en) 2012-12-06
MX2009011369A (es) 2009-12-15
ES2453590T3 (es) 2014-04-08
CN103396399A (zh) 2013-11-20
KR20100017388A (ko) 2010-02-16
US20100130739A1 (en) 2010-05-27
JP5197584B2 (ja) 2013-05-15
EP2679586A1 (en) 2014-01-01
WO2008139894A1 (ja) 2008-11-20
PL2151439T3 (pl) 2014-08-29
US20120258978A1 (en) 2012-10-11
DK2151439T3 (en) 2014-03-10
US9156817B2 (en) 2015-10-13
ES2566327T3 (es) 2016-04-12
KR101456316B1 (ko) 2014-11-03
EP2679586B1 (en) 2016-02-10
RU2009143850A (ru) 2011-06-10
AU2008249329A1 (en) 2008-11-20
EP2151439A1 (en) 2010-02-10
SI2151439T1 (sl) 2014-05-30
US8592435B2 (en) 2013-11-26
US20140221409A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
BRPI0810821A8 (pt) Derivados de anéis aromáticos de seis membros contendo nitrogênio e produtos farmacêuticos contendo os mesmos
AR104417A2 (es) Compuestos de tiadiazolidina, procedimiento para su preparación, composición farmacéutica que lo compone y usos de dichos compuestos
AR055116A1 (es) Compuestos aromaticos como agentes terapeuticos para diabetes y composiciones farmaceuticas que los contienen.
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
AR046845A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
AR061900A1 (es) Compuestos de azabencimidazolilo y composicion farmaceutica
AR061570A1 (es) Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
AR038476A1 (es) Derivados de quinazolina
MXPA03004821A (es) Compuestos de union de ciclofilina carbociclica bisubstutuida y su uso.
BRPI0919020A2 (pt) Uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
NI200800015A (es) Derivados de n-(heteroaril)-1-heteroarilalquil - 1h - indol - 2 - carboxamidas, su preparación y su aplicación en terapéutica.
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
TW200505441A (en) Non-nucleoside reverse transcriptase inhibitorsⅠ
MEP27508A (en) N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
BRPI0518096A (pt) composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos
TW200740806A (en) Bridged N-cyclic sulfonamido inhibitors of gamma secretase
BR0008569A (pt) 2-aminopiridinas contendo anéis fundidos como substituintes
BR0212123A (pt) 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
Musilek et al. Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors—Analogues of SAD-128
CA2555199A1 (en) Peptidylarginine deiminase 4 inhibitor
ES2127875T3 (es) Bencenosulfonil-ureas y -tioureas sustituidas con amino, procedimiento para su preparacion y su utilizacion como productos farmaceuticos.
BR0312702A (pt) Derivados de 3-guanidinocarbonil-1-heteroaril-pirrol, processo de preparação e intermediários desse processo, seu uso como medicamentos e composições farmacêuticas compreendendo os mesmos
AR011483A1 (es) Derivados de la 3-bencilpiperidina, un procedimiento para prepararlos, el empleo de los mismos en la elaboracion de medicamentos, las preparacionesfarmaceuticas que los contienen y un procedimiento para elaborar estas preparaciones farmaceuticas

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: ASUBIO PHARMA CO., LTD (JP)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20100090861/RJ DE 28/09/2010, E NECESSARIO APRESENTAR O DOCUMENTO DE FUSAO COM A DEVIDA LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25D Requested change of name of applicant approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP)

B25B Requested transfer of rights rejected

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]